Current Status and Open Issues Concerning Global Clinical Trials (GCTs) in Japan and East Asia

Koichi Miyazaki, Yasunori Sato, Hideki Hanaoka, Yoshiaki Uyama

研究成果: Article

4 引用 (Scopus)

抄録

When global clinical trials are carried out, it is important to consider the influence of racial and ethnic differences on the outcome. From this viewpoint, global clinical trials in East Asia, where racial differences are estimated to be small, are now attracting close attention. Under such circumstances, we conducted a survey using the data registered with ClinicalTrial.gov to investigate the status of participation of East Asian countries in global clinical trials and differences in the regions selected for drug development between Japanese enterprises and non-Japanese enterprises. This survey revealed that about 90% of all global clinical trials and those involving East Asian countries were sponsored by non-Japanese enterprises. Global clinical trials involving only East Asia have been accepted as one of the development strategies by Japanese enterprises, but this strategy has not spread widely among non-Japanese enterprises.

元の言語English
ページ(範囲)503-508
ページ数6
ジャーナルClinical and Translational Science
10
発行部数6
DOI
出版物ステータスPublished - 2017 11 1
外部発表Yes

Fingerprint

Far East
Japan
Clinical Trials
Industry
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Neuroscience(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

これを引用

Current Status and Open Issues Concerning Global Clinical Trials (GCTs) in Japan and East Asia. / Miyazaki, Koichi; Sato, Yasunori; Hanaoka, Hideki; Uyama, Yoshiaki.

:: Clinical and Translational Science, 巻 10, 番号 6, 01.11.2017, p. 503-508.

研究成果: Article

Miyazaki, Koichi ; Sato, Yasunori ; Hanaoka, Hideki ; Uyama, Yoshiaki. / Current Status and Open Issues Concerning Global Clinical Trials (GCTs) in Japan and East Asia. :: Clinical and Translational Science. 2017 ; 巻 10, 番号 6. pp. 503-508.
@article{cbf5086828814106ba29b45d5c72052e,
title = "Current Status and Open Issues Concerning Global Clinical Trials (GCTs) in Japan and East Asia",
abstract = "When global clinical trials are carried out, it is important to consider the influence of racial and ethnic differences on the outcome. From this viewpoint, global clinical trials in East Asia, where racial differences are estimated to be small, are now attracting close attention. Under such circumstances, we conducted a survey using the data registered with ClinicalTrial.gov to investigate the status of participation of East Asian countries in global clinical trials and differences in the regions selected for drug development between Japanese enterprises and non-Japanese enterprises. This survey revealed that about 90{\%} of all global clinical trials and those involving East Asian countries were sponsored by non-Japanese enterprises. Global clinical trials involving only East Asia have been accepted as one of the development strategies by Japanese enterprises, but this strategy has not spread widely among non-Japanese enterprises.",
author = "Koichi Miyazaki and Yasunori Sato and Hideki Hanaoka and Yoshiaki Uyama",
year = "2017",
month = "11",
day = "1",
doi = "10.1111/cts.12485",
language = "English",
volume = "10",
pages = "503--508",
journal = "Clinical and Translational Science",
issn = "1752-8054",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Current Status and Open Issues Concerning Global Clinical Trials (GCTs) in Japan and East Asia

AU - Miyazaki, Koichi

AU - Sato, Yasunori

AU - Hanaoka, Hideki

AU - Uyama, Yoshiaki

PY - 2017/11/1

Y1 - 2017/11/1

N2 - When global clinical trials are carried out, it is important to consider the influence of racial and ethnic differences on the outcome. From this viewpoint, global clinical trials in East Asia, where racial differences are estimated to be small, are now attracting close attention. Under such circumstances, we conducted a survey using the data registered with ClinicalTrial.gov to investigate the status of participation of East Asian countries in global clinical trials and differences in the regions selected for drug development between Japanese enterprises and non-Japanese enterprises. This survey revealed that about 90% of all global clinical trials and those involving East Asian countries were sponsored by non-Japanese enterprises. Global clinical trials involving only East Asia have been accepted as one of the development strategies by Japanese enterprises, but this strategy has not spread widely among non-Japanese enterprises.

AB - When global clinical trials are carried out, it is important to consider the influence of racial and ethnic differences on the outcome. From this viewpoint, global clinical trials in East Asia, where racial differences are estimated to be small, are now attracting close attention. Under such circumstances, we conducted a survey using the data registered with ClinicalTrial.gov to investigate the status of participation of East Asian countries in global clinical trials and differences in the regions selected for drug development between Japanese enterprises and non-Japanese enterprises. This survey revealed that about 90% of all global clinical trials and those involving East Asian countries were sponsored by non-Japanese enterprises. Global clinical trials involving only East Asia have been accepted as one of the development strategies by Japanese enterprises, but this strategy has not spread widely among non-Japanese enterprises.

UR - http://www.scopus.com/inward/record.url?scp=85021824106&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021824106&partnerID=8YFLogxK

U2 - 10.1111/cts.12485

DO - 10.1111/cts.12485

M3 - Article

C2 - 28675655

AN - SCOPUS:85021824106

VL - 10

SP - 503

EP - 508

JO - Clinical and Translational Science

JF - Clinical and Translational Science

SN - 1752-8054

IS - 6

ER -